|

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

RECRUITINGPhase 1/2Sponsored by First Affiliated Hospital of Fujian Medical University
Actively Recruiting
PhasePhase 1/2
SponsorFirst Affiliated Hospital of Fujian Medical University
Started2025-12-20
Est. completion2026-12-31
Eligibility
Age18 Years – 90 Years
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07363382

Summary

The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant molecular imaging modality in prostate cancer, particularly serving as a complementary tool to PSMA PET for addressing cases with negative or insufficient PSMA expression. It demonstrates substantial value in initial staging (especially in intermediate- and high-risk patients), detecting sites of biochemical recurrence, assessing metastatic lesions (notably in mCRPC), and guiding treatment decisions. 68Ga-G21 and 68Ga-G23 are two novel molecular probes targeting GRPR. This study aims to evaluate their biodistribution and diagnostic performance in prostate cancer and compare them with 68Ga-PSMA-11 PET imaging.

Eligibility

Age: 18 Years – 90 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

* confirmed treated or untreated prostate cancer patients;
* signed written consent.

Exclusion Criteria:

* known allergy against PSMA;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Conditions2

CancerProstate Cancer (Adenocarcinoma)

Interventions2

68Ga-G2168Ga-G23

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.